<DOC>
	<DOCNO>NCT00473967</DOCNO>
	<brief_summary>Na-ASP-2 protein express larval stage N. americanus hookworm life cycle . Vaccination recombinant ASP-2 protect dog hamster infection challenge study . In clinical study hookworm-uninfected adult USA , Na-ASP-2 Hookworm Vaccine safe immunogenic . This study evaluate safety immunogenicity individual live area endemic hookworm infection .</brief_summary>
	<brief_title>Phase 1 Trial Na-ASP-2 Hookworm Vaccine Previously Infected Brazilian Adults</brief_title>
	<detailed_description>- Double-blind , randomize , control Phase 1 clinical trial . - Study site : Americaninhas , Minas Gerais , Brazil . - Number participant : 48 three group 16 , randomize receive either Na-ASP-2 Hookworm Vaccine ( n=36 ) Butang® hepatitis B vaccine ( n=12 ) . - Study duration : 48 week ; participant follow total 42 week . - Immunization schedule : Study day 0 , 56 112 . - Route : IM deltoid muscle . - Dose Na-ASP-2 : 10 , 50 100 µg first , second third dose cohort , respectively . - Dose Alhydrogel® : 800 µg dose Na-ASP-2 .</detailed_description>
	<mesh_term>Hookworm Infections</mesh_term>
	<mesh_term>Ancylostomiasis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Males females 18 45 year , inclusive . Known resident Municipality Novo Oriente de Minas , Minas Gerais , Brazil . Good general health determine mean screening procedure . Completed 3dose albendazole treatment document hookworm infection previous 3 month . Available duration trial ( 42 week ) . Willingness participate study evidence sign informed consent document . Pregnancy determine positive urine βhCG ( female ) . Participant unwilling use reliable contraception method one month follow third immunization ( female ) . Currently lactate breastfeed ( female ) . Inability correctly answer question inform consent comprehension questionnaire . Evidence clinically significant neurologic , cardiac , pulmonary , hepatic , rheumatologic , autoimmune , renal disease history , physical examination , and/or laboratory study . Behavioral , cognitive , psychiatric disease opinion investigator affect ability volunteer understand cooperate study protocol . Laboratory evidence liver disease ( alanine aminotransferase [ ALT ] great 64 U/l [ females ] great 58 U/l [ male ] ) . Laboratory evidence renal disease ( serum creatinine great 1.1 mg/dl [ female ] great 1.3 mg/dl [ male ] , trace protein blood urine dipstick test ) . Laboratory evidence hematologic disease ( absolute leukocyte count &lt; 3000/mm3 &gt; 12.5 x 103/mm3 ; hemoglobin &lt; 10.3 g/dl [ female ] &lt; 11.0 g/dl [ male ] ; absolute lymphocyte count &lt; 900/mm3 ; platelet count &lt; 120,000/mm3 ) . Other condition opinion investigator would jeopardize safety right volunteer participate trial would render subject unable comply protocol . Participation another investigational vaccine drug trial within 30 day start study . Volunteer medical , occupational , family problem result alcohol illicit drug use past 12 month . History severe allergic reaction anaphylaxis . Severe asthma define need regular use inhaler emergency clinic visit hospitalization within last 6 month . Positive ELISA HCV . Positive ELISA HBsAg . Known immunodeficiency syndrome . Use corticosteroid ( exclude topical nasal ) immunosuppressive drug within 30 day start study . Receipt live vaccine within past 4 week kill vaccine within past 2 week prior entry study . History surgical splenectomy . Receipt blood product within past 6 month . Previous receipt primary series hepatitis B vaccine . History allergy yeast .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Vaccine</keyword>
	<keyword>Hookworm</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Na-ASP-2</keyword>
</DOC>